A new type of weight loss jab can help maintain weight reductions by tackling the underlying causes of obesity, scientists have said. The drug, which is called RES-010, is designed to block an RNA ...

PEDS, the first Phase 3 trial to evaluate the safety and efficacy of Mounjaro, a GIP/GLP-1 dual receptor agonist, in children and adolescents with type 2 diabetes inadequately controlled with ...

Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better ...

In a trial comparing two oral GLP-1s, orforglipron was superior to semaglutide for glycemic control and weight loss in ...

The link between diabetes and dementia is becoming increasingly clear. New research shows how blood sugar problems affect ...

Eli Lilly (NYSE:LLY) said that data from its study showed that its oral GLP-1 drug, orforglipron, was more effective against ...

Metformin use was associated with lower risks for dementia and all-cause mortality across the overweight and obese BMI spectrum.

The 7- and 14-mg semaglutide doses included in Lilly’s trial match those of Novo’s Rybelsus, an oral version of the GLP-1 semaglutide that is approved as a first-line treatment option in type 2 ...

Metformin is a medication that millions of people take to manage their blood sugar levels. It’s one of the most common ...

SHANGHAI (Reuters) -U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership ...